FDA approves "Game Changer" Semaglutide for Weight Loss

websitebuilder • June 8, 2021

FDA Approves 'Game Changer' Semaglutide for Weight Loss -

June 7, 2021

medical weight loss, wegovy, now available at  at Dr. Mantor's Wrinkle and Weight Solutions, LLC in Westerville, OH

The US Food and Drug Administration (FDA) has approved a 2.4 mg/week subcutaneous dose of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy, Novo Nordisk) for weight loss, the company has announced.


Specifically, this drug format and dosage are approved as an adjunct to a reduced-calorie diet and increased physical activity to treat adults who have obesity (body mass index [BMI] ≥ 30 kg/m2) or are overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.


Semaglutide "induces weight loss by reducing hunger, increasing feelings of fullness, and thereby helping people eat less and reduce their calorie intake," according to a company statement.

Novo Nordisk plans to launch Wegovy later this month in the United States. The prescribing information can be found here.


The weight loss drug is currently under review by the European Medicines Agency.

Several experts told Medscape Medical News that they believe the approval of this drug — as long as it is reimbursed — has the potential to change the paradigm of care when it comes to weight loss.

"Game Changer" Drug Tested in STEP Clinical Trial Program


The favorable FDA ruling is based on results from the Semaglutide Treatment Effect in People With Obesity (STEP) program of four phase 3 clinical trials that tested the drug's safety and efficacy in more than 4500 adults with overweight or obesity who were randomized to receive a reduced calorie meal plan and increased physical activity (placebo) or the lifestyle intervention plus semaglutide.


The four 68-week trials of subcutaneous semaglutide 2.4 mg/week versus placebo were published in the New England Journal of Medicine (STEP 1), The Lancet (STEP 2), and JAMA (STEP 3STEP 4) in February and March 2021.

As previously reported by Medscape Medical News, all trials were in adults with overweight or obesity:

  • STEP 1 was in 1961 adults.
  • STEP 2 was in 1210 adults who also had diabetes.
  • STEP 3 was in 611 adults, where those in the treatment group also underwent an intensive lifestyle intervention.
  • STEP 4 was in 803 adults who had reached a target dose of 2.4 mg semaglutide after a 20-week run-in (and the trial examined further weight-loss in the subsequent 48 weeks).


In the STEP 1, 2, and 4 trials of individuals with overweight and obesity, those in the semaglutide groups attained a 15% to 18% weight loss over 68 weeks.


The dosage was well-tolerated. The most common side effects were gastrointestinal, and they were transient and mild or moderate in severity.   


The side effects, contraindications, and a black box warning about thyroid C-cell tumors are spelled out in the prescribing information.


A coauthor of the STEP 1 trial, Rachel Batterham, MBBS, PhD, of the Centre for Obesity Research at University College London, UK, said at the time of publication: "The findings of this study represent a major breakthrough for improving the health of people with obesity."


"No other drug has come close to producing this level of weight loss — this really is a game changer. For the first time, people can achieve through drugs what was only possible through weight-loss surgery," she added. 


Welcome Addition, But Will Insurance Coverage, Price Thwart Access?

Invited to comment on the FDA approval, Thomas A. Wadden, PhD, from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and lead author of STEP 3, told Medscape Medical News in an email that "semaglutide 2.4 mg appears to be the breakthrough in weight management that healthcare providers and their patients with obesity have been waiting for."


The mean 15% weight loss at 68 weeks is nearly twice what is seen with other FDA-approved anti-obesity medications, he noted, and moreover, 70% of patients taking semaglutide lost at least 10% of their initial weight, which is associated with clinically meaningful improvements in obesity-related type 2 diabetes, hypertension, obstructive sleep apnea, and impaired quality of life.


And "nearly one third of users are likely to lose 20% or more of their starting weight, an outcome which eludes traditional diet and exercise interventions and which approaches weight losses produced by the most widely performed bariatric surgery, sleeve gastrectomy (with mean losses of 25% of initial weight at 1 year)," Wadden stressed.


Thus, "the efficacy of semaglutide 2.4 mg, combined with its favorable safety profile, makes this medication a potential game changer," he summarized, echoing Batterham.


However, insurance coverage and price could block uptake.


"I hope that the millions of people — in the US and worldwide — who could benefit from this medication eventually will have access to it," said Wadden. "In the US, the coverage of anti-obesity medications by insurers and employers will need to improve to ensure this happens, and the medication must be reasonably priced. These changes are critical to making this medication the game changer it could be."

"This approval is an important development," Scott Kahan, MD, director of the National Center for Weight and Wellness, Washington, DC, who was not involved in clinical trials of the drug, similarly told Medscape Medical News in an email.


"In a field with relatively few medication options, the availability of additional obesity pharmacotherapy agents is welcome," he said. "In particular, semaglutide has shown impressive efficacy and safety data; as such it should be a valuable clinical option for many patients."


However, it is concerning that "access to obesity treatments has traditionally been a challenge," Kahan warned. "Novo Nordisk's other obesity medication, Saxenda, has been a valuable tool, but one that exceedingly few patients are able to utilize due to minimal insurance reimbursement and very high cost.""It remains to be seen how accessible semaglutide will be for patients," according to Kahan. "Still, if the challenge of limited coverage and high cost can be mitigated, this medication has a chance to significantly change the current paradigm of care, which until now has included minimal use of pharmacotherapy outside specialty clinics," he maintained.


Lower-Dose Injectable and Pill Already Approved for Diabetes

Subcutaneous semaglutide at doses up to 1 mg/week (Ozempic, Novo Nordisk), which comes as prefilled pens at doses of 0.5 mg or 1.0 mg, is already approved for the treatment of type 2 diabetes.


The company is also applying for approval for a higher dose of semaglutide, 2 mg/week, for use in type 2 diabetes, and has just resubmitted its label expansion application to the FDA, after the agency issued a refusal to file letter in March.

And in September 2019, the FDA approved oral semaglutide (Rybelsus, Novo Nordisk), in doses of 7 and 14 mg/day, to improve glycemic control in type 2 diabetes, making it the first GLP-1 receptor agonist available in tablet form.


CVOT and Oral Format Trials for Obesity on the Horizon

The ongoing Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) trial will shed light on cardiovascular outcomes after 2.5 to 5 years in patients with cardiovascular disease and overweight or obesity but without type 2 diabetes. Participants will receive semaglutide in doses up to a maximum of 2.4 mg/week, or placebo, as an adjunct to lifestyle recommendations focused on cardiovascular risk reduction. The study is expected to complete in 2023.


And Novo Nordisk plans to initiate a global 68-week phase 3 trial in the second half of 2021 on the efficacy and safety of oral semaglutide 50 mg compared with placebo in 1000 people with obesity or overweight and comorbidities.


Semaglutide will be available later this month for our clients at Dr. Mantor's Wrinkle and Weight Solutions, LLC. If you would like additional information regarding our Physician and Registered Dietician, weight management programs, please give us a call at 614-891-2000 or schedule 24/7 online @


https://WrinkleandWeight.com



Dr. Gina K. Mantor has been practicing at her medical spa in Westerville, Ohio for 13 years and is Board Certified in Internal Medicine, as well as, Board Certified by the American Board of Obesity Medicine (ABOM) as an ABOM diplomate. She was recently named the Director of Cardiopulmonary Services with Central Ohio Primary Care Physicians (COPC). She has helped hundreds of her clients, throughout Central Ohio and beyond, maintain a healthy weight and lifestyle since opening her medical spa in 2008.



Dr. Mantor's Wrinkle and Weight Solutions, LLC

6982 Worthington Road

Westerville, OH 43082

614-891-2000

WrinkleandWeight.com


#medicalspa #internalmedicine #weightloss #obesity #adom #registereddietician #rd #westervilleohio #powellohio #lewiscenterohio #galenaohio #delawareohio #worthingtonohio #weightlosstransformation #centralohioprimarycare #medicalweightloss #weightlossspa #physicianmanaged #galenaohio #newalbanyohio #lewiscenter #westervilleohio #bigwalnut #sunburyohio #powellohio #columbusohio #delawareohio #worthingtonohio


Experience Emsculpt Neo for enhanced muscle building, faster recovery, and improved mobility.
March 25, 2025
Boost muscle growth, recovery, and mobility with the innovative Emsculpt Neo and functional wellness solutions
Elevate your style with our popular threads. Enjoy free expert consultations to achieve your desired look.
By Gina Mantor March 20, 2025
New Beauty Reports on the Popularity of Thread Lifts!
Refresh and Rejuvenate with Dermaplaning. Read more on the procedure here.
March 13, 2025
Say goodbye to dull skin and hello to radiance with our professional dermaplane treatment. Start glowing!
Overcome ED with the Magnym™ Procedure, designed to rejuvenate confidence and transform relationship
March 13, 2025
In the realm of men's health, erectile dysfunction (ED) emerges as a prevalent issue, impacting not just physical performance but also mental well-being and emotional stability. For many, it stands as a silent barrier to intimacy, overshadowing confidence and self-esteem. Fortunately, innovative solutions like the Magnym™ Procedure offer hope and empowerment. This treatment is designed to address the root causes of ED, transforming challenges into triumphs and revitalizing your confidence in every aspect of life.
diastasis recti treatment with emsculpt neo
By websitebuilder March 2, 2025
One of the best and newest ways to rid yourself of Diastasis Recti is by completing a series of Emsculpt NEO treatments. Along with improving muscle tone and burning fat, this revolutionary treatment that can also be used to help treat Diastasis Recti.
Discover key differences between Emsculpt and Dysport on Dr. Mantor's Wrinkle and Weight Solutions blog.
March 1, 2025
Botox vs Dysport: What's the Difference?
Transform with the Y LIFT®: Youthful Results in 30 Minutes
By Gina Mantor February 21, 2025
Unlock a more youthful version of yourself with the Y LIFT®, an advanced cosmetic procedure designed to redefine facial contours into the perfect 'Y' shape. By focusing on the cheekbones and jawline, this technique offers a lifted appearance without traditional surgery. The Y LIFT® employs a blunt titanium tool and FDA-approved fillers to sculpt and support facial muscles, delivering results that last up to four years. This innovative method avoids incisions and ensures minimal dyiscomfort, making it ideal for those seeking a non-surgical facelift. Now is the time to achieve the youthful, vibrant look you've always wanted. Schedule your complimentary consultation to learn how the Y LIFT® can enhance your natural beauty with precision and care.
Enhance your beauty with expert PDO thread lifts by MD Injector Dr. Gina Mantor. Free consultations
November 24, 2024
PDO thread lifts for a rejuvenated appearance. Trusted MD injector Dr. Gina Mantor offers free consultations.
Now, with FDA clearance for treatment of the neck, BOTOX® offers a new way to address neck wrinkles
October 24, 2024
When it comes to tackling the signs of aging, Botox has long been a go-to solution for smoothing out facial lines. Now, with FDA clearance for treatment of the neck, Botox offers a new way to address those pesky neck wrinkles that can add years to your appearance. If you're seeking an effective, non-surgical way to rejuvenate your neck, read on to discover how Botox can help you achieve a more youthful look.
Breast Cancer Awareness month, what you need to know
October 2, 2024
Breast Cancer: Recognizing the Signs and Symptoms Understanding the usual appearance and feel of your breasts is an essential aspect of maintaining breast health
More Posts
Share by: